CIRM Funded Clinical Trials
MSC engineered to produce BDNF for the treatment of Huntington’s disease
Disease Area:
Huntington's Disease
Trial Sponsor:
The Regents of the University of California, on behalf of its Davis campus
Trial Stage:
Phase 1/2
Trial Status:
Completed
Targeted Enrollment:
29
ClinicalTrials.gov ID:
Details:
A team at UC Davis plans to use bone marrow derived mesenchymal stem cells to deliver a growth factor, called BDNF, to patients’ brains in order to reduce the death of nerve cells that occurs in Huntington’s Disease (HD). In preparation for such a clinical trial study, the team completed a CIRM-funded observational trial in a group of HD patients to study the progression of disease.
Updates:
This trial is completed.
